Alnylam Pharma (ALNY) Tops Q1 EPS by 65c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
May 1, 2019 8:00 AM EDTAchieved First Quarter 2019 ONPATTRO® Global Net Product Revenues of $26.3 Million with Over 400 Patients on Commercial Product Worldwide
Achieved Positive Results in ENVISION Phase 3 Study of Givosiran
Formed Broad Collaboration with Regeneron to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Strengthened Balance Sheet with New Equity-Based Capital and Partnership-Based Funding
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
